Demand Spurs Efforts to Improve Recruitment, Retention

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 8
Volume 15
Issue 8

Focus groups, mentoring, and expanded recruitment efforts have helped Roswell Park Cancer Institute (RPCI) keep its vacancy rate low in the midst of a nursing shortage

BOSTON—Focus groups, mentoring, and expanded recruitment efforts have helped Roswell Park Cancer Institute (RPCI) keep its vacancy rate low in the midst of a nursing shortage, said Denise Rutkowski, MS, RN, CRC, OCN, nurse recruiter and retention coordinator at RPCI. "The average age of our nurses is 44. Our average length of service is about 11 years. Our current vacancy rate is 6.5%, compared to 20% nationally," Ms. Rutkowski said at the Oncology Nursing Society 31st Annual Congress (abstract 284).

To increase retention, focus groups are held with new nurses and the Human Resources Department, to determine why the nurses selected RPCI, which factors helped them become acclimated to their new position, and what needs to be changed to help with the next round of orientation. In addition, Roswell Park connects new nurses with mentors.

Roswell Park is beginning to focus its recruitment efforts not only on the Western New York region but across the country, to attract nurses who have family in this region or wish to relocate. "We believe we can offer oncology nurses a dynamic work environment and one in which they can be professionally satisfied," Ms. Rutkowski concluded.

Recent Videos
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Related Content